case_images: PMC5874899_01
case_images: A representative data showing comparison of biomechanics outcome metrics between MPK and PKA. Panels (A1-A4) are for participant CS01. (A1) compares the ankle joint kinematics between PKA, MPK1- (Genium), and healthy data (Winter,) for the ipsilateral side for CS01. (A2) Shows comparison of the ratio of peak VGRF (Fz1/Fz2) during the stance phase between MPK-1 (Genium), PKA, and healthy data (Winter,). It was observed that using the PKA led to a VGRF behavior closer to healthy limb on both the contralateral and the ipsilateral sides. (A3) EMG activation profile between MPK-1(Genium) and PKA at right and left side L3 erector spinae muscles in low back. The EMG activation profile was indexed as area under the curve (AUC) of the EMG signal. It can be observed that using PKA reduces the asymmetry in EMG activation between the LES-L3 and the RES-L3 muscles. (A4) EMG activation (AUC) for lower extremity muscles MGC and RF on contralateral side. It was observed that using the PKA lead to higher activation in the MGC and reduced activation in the RF on the contralateral side. Panels (B1-B4) are for participant CS02. (B1) compares the ankle joint kinematics between PKA, MPK2- Rheo-3, and healthy data (Winter,) for the ipsilateral side for CS02. (B2) Comparison of the ratio of peak VGRFs during the stance phase between MPK-2 (Rheo-3), PKA, and healthy data (Winter,). It was observed that using the PKA led to a VGRF behavior close to healthy limb on both, the contralateral and the ipsilateral sides. (B3) EMG activation profile between MPK-2 (Rheo-3) and PKA at right and left side L3 erector spinae muscles in low back. The EMG activation profile was indexed as area under the curve (AUC) of the EMG signal. It can be observed that using PKA reduces the asymmetry in EMG activation between the LESL3 and the RESL3 muscles. (B4) EMG activation (AUC) for lower extremity muscles MGC and the RF on contralateral side. It was observed that using the PKA lead to higher activation in the MGC and reduced activation in the RF on the contralateral side.
case_images: fnins-12-00134-g0001.jpg
case_images: PMC5874899_01_fnins-12-00134-g0001.jpg
case_images: F1
case_images: Summary of outcome metrics from the modified graded treadmill test (GTT). Panels (A1-A6) are GTT outcome metrics for participant CS01 and panels (B1-B6) are GTT outcome metrics for participant CS02. (A1,B1) compares the cadence during the GTT between the MPK-1(Genium) vs. PKA and MPK-2(Rheo-3) vs. PKA respectively. (A2,B2) compares the EE during GTT between the MPK-1 (Genium) vs. PKA and MPK-2 (Rheo-3) vs. PKA respectively. (A3,B3) Compares the coefficient of variation (CV%) for the stride time between the MPK-1(Genium) vs. PKA (in panel A3) and MPK-2(Rheo-3) vs. PKA (in panel B3) respectively for the contralateral limb. (A4,B4) shows the stepwise stride time for the contralateral side during a representative 1 min treadmill walk for MPK-1(Genium) vs. PKA [(in panel A4): at treadmill speed of 1.4 m/s (*preferred treadmill speed of the participant CS01)] and MPK-2(Rheo-3) vs. PKA [(in panel B4): at treadmill speed of 1 m/s ( preferred treadmill speed of the participant CS02)]. (A5,B5) Compares the coefficient of variation (CV%) for the stride time between the MPK-1(Genium) vs. PKA (in panel A5) and MPK-2(Rheo-3) vs. PKA (in panel B5) respectively for the ipsilateral limb. (A6,B6) shows the stepwise stride time for the contralateral side during a representative 1 min treadmill walk for MPK-1(Genium) vs. PKA [(in panel A6): at treadmill speed of 1.4 m/s] and MPK-2(Rheo-3) vs. PKA [(in panel B6): at treadmill speed of 1 m/s].
case_images: fnins-12-00134-g0002.jpg
case_images: PMC5874899_01_fnins-12-00134-g0002.jpg
case_images: F2